2020
Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma
Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Current Oncology Reports 2020, 22: 35. PMID: 32170461, DOI: 10.1007/s11912-020-0895-y.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaSystemic therapyRenal cell carcinomaCytoreductive nephrectomySurgical therapyCell carcinomaManagement of mRCCPoor-risk metastatic renal cell carcinomaInitial systemic therapyReviewThe treatment landscapeTargeted therapy eraUpfront cytoreductive nephrectomyViable treatment approachSequence of surgeryTherapy eraTreatment landscapeUnselected patientsSurgical managementSummaryRecent evidenceRecent FindingsOneTreatment approachesNephrectomyTherapyOptimal rolePatients
2019
Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Abello A, Kenney P. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2019, 411-435. DOI: 10.1007/978-3-030-24378-4_24.Peer-Reviewed Original ResearchRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaDisease-free survivalHigh-risk subsetVenous tumor thrombusTyrosine kinase inhibitorsAdjuvant settingCytoreductive nephrectomyUnresectable diseaseAdjuvant therapyAdvanced diseaseNeoadjuvant therapyOverall survivalTumor thrombusGenitourinary malignanciesPartial nephrectomySignificant causeTherapyEffective agentNephrectomyMonoclonal antibodiesKinase inhibitorsDisease
2017
PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY?
Keskin S, Petros F, Yu K, Aboshady Y, Borregales L, Kenney P, Matin S, Karam J, Wood C. PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY? Journal Of Urology 2017, 197: e65-e66. DOI: 10.1016/j.juro.2017.02.228.Peer-Reviewed Original Research
2015
Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules
Adibi M, Kenney PA, Thomas AZ, Borregales LD, Nogueras-González GM, Wang X, Devine CE, Karam JA, Wood CG. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. European Urology 2015, 69: 352-360. PMID: 26382085, DOI: 10.1016/j.eururo.2015.08.053.Peer-Reviewed Original ResearchConceptsLung metastasis-free survivalIndeterminate pulmonary nodulesRenal cell carcinomaAdvanced renal cell carcinomaPulmonary metastasesCell carcinomaPulmonary nodulesMultivariable Cox regression modelsRenal cell carcinoma patientsRadical nephrectomy patientsCell carcinoma patientsMetastasis-free survivalCox regression modelIndividualized risk stratificationAvailable preoperative imagingKidney cancer patientsSmall lung nodulesThree yrNephrectomy patientsPreoperative chestOverall cohortCarcinoma patientsDistant metastasisPathological variablesRadical nephrectomyMucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes
Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, Karam JA. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU International 2015, 116: 85-92. PMID: 25395040, DOI: 10.1111/bju.12992.Peer-Reviewed Original ResearchConceptsSpindle cell carcinomaCell carcinomaSingle-institution retrospective analysisContrast-enhanced computed tomographyRenal cell carcinoma variantsPT3a diseaseOncological outcomesSalvage surgeryClinical characteristicsMetastatic diseaseFemale predominanceMedian ageClinical outcomesRadical nephrectomyFemale predilectionExcellent outcomesPathological featuresCarcinoma variantsSarcomatoid dedifferentiationActive surveillanceHistological featuresRetrospective analysisEnergy ablationComputed tomographyPapillary RCC
2014
Preoperative Predictors of Pathological Lymph Node Metastasis in Patients with Renal Cell Carcinoma Undergoing Retroperitoneal Lymph Node Dissection
Babaian KN, Kim DY, Kenney PA, Wood CG, Wong J, Sanchez C, Fang JE, Gerber JA, Didic A, Wahab A, Golla V, Torres C, Tamboli P, Qiao W, Matin SF, Wood CG, Karam JA. Preoperative Predictors of Pathological Lymph Node Metastasis in Patients with Renal Cell Carcinoma Undergoing Retroperitoneal Lymph Node Dissection. Journal Of Urology 2014, 193: 1101-1107. PMID: 25390078, DOI: 10.1016/j.juro.2014.10.096.Peer-Reviewed Original ResearchConceptsRetroperitoneal lymph node dissectionLymph node dissectionRenal cell carcinomaNode dissectionPositive lymph nodesRecurrence-free survivalLymph node metastasisCell carcinomaECOG PSPreoperative predictorsLymph nodesDistant metastasisNode metastasisLocal symptomsCN stageM0 renal cell carcinomaAdvanced renal cell carcinomaPathological lymph node metastasisPreoperative clinical predictorsKaplan-Meier methodLactate dehydrogenasePatients 131PN1 casesPN0 diseasePredictive nomogram1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection?
Babaian K, Kenney P, Karam J, Wood C. 1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection? European Urology Open Science 2014, 13: e1042. DOI: 10.1016/s1569-9056(14)61024-1.Peer-Reviewed Original ResearchMP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION?
Babaian K, Kenney P, Kim D, Qiao W, Karam J, Wood C. MP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION? Journal Of Urology 2014, 191: e701. DOI: 10.1016/j.juro.2014.02.1920.Peer-Reviewed Original Research
2013
Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma
Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, Maity T, Yang SF, Lin X, Wood CG. Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma. Clinical Cancer Research 2013, 19: 6461-6472. PMID: 24122794, PMCID: PMC4191899, DOI: 10.1158/1078-0432.ccr-13-1284.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsCarcinogenesisCarcinoma, Renal CellCell Line, TumorCell MovementDrug Resistance, NeoplasmFemaleHuman Umbilical Vein Endothelial CellsHumansIndolesKidney NeoplasmsLysophospholipidsMiceMice, Inbred BALB CMice, NudeMicrovesselsNeoplasm InvasivenessPhosphoric Diester HydrolasesPyrrolesSignal TransductionSunitinibTranscriptomeTumor BurdenXenograft Model Antitumor AssaysConceptsLPA receptor 1Lysophosphatidic acidATX-LPAResistance of RCCRenal cell carcinomaGene expression profilesExtracellular lysophospholipase DRCC cell linesTarget genesCell motilityEndothelial cellsExpression profilesIntracellular signalingInvasion responsesRCC tumorigenesisHuman renal cell carcinomaSignaling AxisSensitivity of RCCRCC cellsFunctional roleXenograft modelAltered expressionRenal tumorigenesisCell carcinomaLysophospholipase DUnified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney P, Wood C. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2013, 155-177. DOI: 10.1007/978-1-4614-7236-0_10.Peer-Reviewed Original ResearchSystemic therapyBenefit of cytoreductionTargeted therapy eraVenous tumor thrombusRenal cell carcinomaTyrosine kinase inhibitorsAdjuvant settingUnresectable diseaseAdvanced diseaseCytoreductive surgeryNeoadjuvant therapyTherapy eraAdjuvant therapyMetastatic RCCTumor thrombusGenitourinary malignanciesCell carcinomaPartial nephrectomySurgeryTherapyEffective agentMonoclonal antibodiesKinase inhibitorsDiseaseCurrent rolePreoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus
Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V. Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. Journal Of Urology 2013, 190: 452-457. PMID: 23434945, DOI: 10.1016/j.juro.2013.02.033.Peer-Reviewed Original ResearchConceptsPreoperative pulmonary embolismCancer-specific survivalRenal cell carcinomaPulmonary embolismPoor postoperative outcomesCell carcinomaSpecific survivalVenous thrombiPostoperative outcomesMetastatic renal cell carcinomaCox proportional hazards analysisWorse cancer-specific survivalConsecutive patient recordsHigh-level thrombusProportional hazards analysisHigher T stagePostoperative disease recurrencePerioperative mortalityMedian followupDisease recurrenceTumor thrombusT stageTertiary hospitalEarly mortalityMulticenter study
2012
Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial
Kenney PA, Wood CG. Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. European Urology 2012, 62: 182-183. PMID: 22640859, DOI: 10.1016/j.eururo.2012.04.013.Peer-Reviewed Original ResearchIntegration of Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney PA, Wood CG. Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. Urologic Clinics Of North America 2012, 39: 211-231. PMID: 22487764, DOI: 10.1016/j.ucl.2012.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalCarcinoma, Renal CellChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansImmunotherapyKidney NeoplasmsMaleNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm StagingNephrectomyPrognosisRadiotherapy, AdjuvantRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaAdvanced nonmetastatic diseaseUpfront cytoreductive nephrectomyIntegration of surgeryCytoreductive nephrectomyCytoreductive surgeryNeoadjuvant therapyNonmetastatic diseaseAdjuvant therapyMetastatic diseaseAppropriate patientsTherapySurgeryDiseaseCurrent roleNephrectomyFurther studiesCarcinomaPotential benefitsPatientsTrials